# Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions

> **NCT00814346** · PHASE2 · COMPLETED · sponsor: **Ipsen** · enrollment: 49 (actual)

## Conditions studied

- Alzheimer's Disease
- Cognitive Impairment

## Interventions

- **DRUG:** EGb761®
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00814346
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2019-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00814346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00814346, "Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00814346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*